TTNP Stock Overview
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Titan Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.97 |
52 Week High | US$16.60 |
52 Week Low | US$5.00 |
Beta | 1.35 |
1 Month Change | -3.63% |
3 Month Change | 30.77% |
1 Year Change | -55.68% |
3 Year Change | -86.06% |
5 Year Change | -99.30% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?
Jul 10Titan Pharma regains Nasdaq listing compliance
Dec 16Titan Pharmaceuticals announces 1-for-30 reverse stock split
Nov 30Titan Pharmaceuticals EPS misses by $0.01, beats on revenue
Nov 16Titan Pharma closes debt settlement and JT-09 acquisition
Nov 02Titan Pharma to raise $8M in stock offering
Oct 28Shareholder Returns
TTNP | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -1.8% | -0.6% | 1.0% |
1Y | -55.7% | 10.6% | 21.9% |
Price Volatility
TTNP volatility | |
---|---|
TTNP Average Weekly Movement | 14.5% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 4 | David Lazar | www.titanpharm.com |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Titan Pharmaceuticals, Inc. Fundamentals Summary
TTNP fundamental statistics | |
---|---|
Market cap | US$6.37m |
Earnings (TTM) | -US$5.57m |
Revenue (TTM) | US$184.00k |
34.6x
P/S Ratio-1.1x
P/E RatioIs TTNP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TTNP income statement (TTM) | |
---|---|
Revenue | US$184.00k |
Cost of Revenue | US$1.91m |
Gross Profit | -US$1.73m |
Other Expenses | US$3.84m |
Earnings | -US$5.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -6.09 |
Gross Margin | -939.67% |
Net Profit Margin | -3,026.63% |
Debt/Equity Ratio | 7.5% |
How did TTNP perform over the long term?
See historical performance and comparison